



Curriculum Vitae Europass

First Name / Surname **Valerio Nardone, M.D.,**

Address(es) Department of Precision Medicine, University of Campania “L. Vanvitelli”,
Naples

Telephone(s) +393202639805 +3908118775069

E-mail Valerio.nardone@unicampania.it
valerionardone@pec.it

Nationality Italian

Date of birth (mm/dd/yyyy) 06/16/1985

Sex M

Occupational field Associate Professor

Department of Precision Medicine, University of Campania “L. Vanvitelli”,
Naples

Previous experience From 10/16/2016 to 11/15/2017 and from 12/20/2017 to 09/15/2018
Professional assignment as external collaborator at Radiotherapy Unit of
University Hospital of Siena
From 01/10/2018 to 15/05/2021 Radiation Oncologist at Unit of Radiation
Oncology, Ospedale del Mare, Naples, Via E. Russo,– 80147 Naples, Italy;
From 16/05/2021 to 15/05/2024 Assistant Professor at Department of Precision
Medicine, University of Campania “L. Vanvitelli”, Naples

Education and training

Specialization Radiation Oncology

Date 06 July 2016

Date 2010

Degree M.D., School of Medicine and Surgery, University of Siena (Italy)
Summa cum laude.

Date 2011

Degree Medical licensure.

Date 20 September 2018

Degree	II level University Master Degree (MsC) in “Farmaci oncologici e radioterapia: biologia e clinica”, Università of Brescia, cum Laude
Date	31 November 2023
Qualification	National scientific qualification as Full Professor (procedure for the Italian University Professor position recruiting, based on rigorous scientific qualification criteria).
Additional information	Current Membership of the following Scientific Societies: Associazione Italiana di Radioterapia Oncologica (AIRO) Member of the Italian Association of Radiotherapy and Oncology, Advisor of Young Section (Consigliere Airo Giovani) 2018-2022. Advisor of Thoracic Oncology Section (Consigliere Gruppo di studio in Oncologia Toracica) 2020/2021; Advisor of Gastroenterology Oncology Section (Consigliere Gruppo di Studio Tumori Gastrointestinali) 2022/2023; Member of Scientific Committee AIRO 2022/2025; Co-Investigator in numerous clinical trials, according to Good Clinical Practice.
Prizes and Awards	Cureus Award (2nd place) in the competition “Frameless stereotactic radiosurgery” with the article “Prognostic Value of MR Imaging Texture Analysis in Brain Non-Small Cell Lung Cancer Oligo-Metastases Undergoing Stereotactic Irradiation” in 2015. AIRB Award 2017 (Best Oral Communication) at AIRO National Congress 2017. Title of the Communication: “Texture analysis in RMN come fattore predittivo di risposta patologica in pazienti con eteroplasia del retto sottoposti a trattamento chemio-radioterapico neoadiuvante”. AIRO Award for Best Young Project at AIRO National Congress 2019. Title of the Project: PROTEOMIC AND GENOMIC PILOT ANALYSIS IN OLIGOMETASTATIC/OLIGOPROGRESSIVE NON SMALL CELL LUNG CANCER (NSCLC) TREATED WITH STEREOTACTIC BODY RADIATION THERAPY (SBRT). Best Radiation Oncologist at II “Carla Russo Award” for Brain Tumours, released on December 2020. Winner of the “Bando di Ateneo per il finanziamento di progetti di ricerca fondamentale ed applicata dedicata ai Giovani Ricercatori” 2022 (68.000 euro financed). Principal Investigator for Multicenter study “Radioterapia radicale in pazienti Anziani affetti da neoplasia del Polmone non a piccole cellule localmente avanzato: studio retrospettivo multicentrico della valutazione dell’impatto della

Sarcopenia sull'Outcome del trattamento radioterapico (studio RAPSO)."

Principal Investigator for multicenter prospective study "Musicoterapia in pazienti sottoposti a Radioterapia: studio prospettico multicentrico sulla valutazione dell'ansia, MUSic listening and Anxiety in patients undergoing RT, MUSA-RT Trial"

Principal Investigator for Monocenter prospective study "CARDioimaging in pazienti con Eteroplasia polmonare sottoposti a trattamento RadioTerapico sul distretto toracico: studio prospettico monocentrico della valutazione della tossicità acuta e tardiva mediante cardioTC e cardioRM (Studio CARE-RT)"

Principal Investigator for Multicenter study "Radioterapia Adiuvante in pazienti affetti da neoplasia del Polmone non a piccole cellule localmente avanzato sottoposti a Chirurgia: studio retrospettivo multicentrico della valutazione della Tossicità Acuta e Tardiva (studio RAC-TAC)."

Scientific Publication

1. Tini, P.; Belmonte, G.; Toscano, M.; Miracco, C.; Palumbo, S.; Pastina, P.; Battaglia, G.; Nardone, V.; Butorano, M.A.G.M.; Masucci, A.; et al. Combined epidermal growth factor receptor and beclin1 autophagic protein expression analysis identifies different clinical presentations, responses to chemo- and radiotherapy, and prognosis in glioblastoma. *BioMed Research International* 2015, 2015, doi:10.1155/2015/208076.
2. Nardone, V.; Botta, C.; Caraglia, M.; Martino, E.C.; Ambrosio, M.R.; Carfagno, T.; Tini, P.; Semeraro, L.; Misso, G.; Grimaldi, A.; et al. Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse. *Cancer Biol Ther* 2016, 17, 1213-1220, doi:10.1080/15384047.2016.1235666.
3. Tini, P.; Pastina, P.; Nardone, V.; Sebaste, L.; Toscano, M.; Miracco, C.; Cerase, A.; Pirtoli, L. The combined EGFR protein expression analysis refines the prognostic value of the MGMT promoter methylation status in glioblastoma. *Clinical Neurology and Neurosurgery* 2016, 149, doi:10.1016/j.clineuro.2016.07.023.
4. Tini, P.; Nardone, V.; Pastina, P.; Battaglia, G.; Sebaste, L.; Pirtoli, L. In Regard to Kubicek et al. *International Journal of Radiation Oncology Biology Physics* 2016, 96, doi:10.1016/j.ijrobp.2016.08.004.
5. Nardone, V.; Tini, P.; Sebaste, L.; Biondi, M.; Buonamici, F.B.; Pirtoli, L. Bone structure texture analysis as a potential tool to estimate radiation induced insufficiency fracture risk. *Radiotherapy and Oncology* 2016, 120, 184-184, doi:10.1016/j.radonc.2016.06.001.
6. Pastina, P.; Nardone, V.; Croci, S.; Battaglia, G.; Vanni, F.; Bellan, C.; Barbarino, M.; Ricci, V.; Costantini, S.; Capone, F.; et al. Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients. *J Thorac Dis* 2017, 9, doi:10.21037/jtd.2017.08.68.
7. Pastina, P.; Nardone, V.; Botta, C.; Croci, S.; Tini, P.; Battaglia, G.; Ricci, V.; Cusi, M.G.; Gandolfo, C.; Misso, G.; et al. Radiotherapy prolongs the survival of advanced non-smallcell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev). *Oncotarget* 2017, 8, doi:10.18632/oncotarget.20411.
8. Nardone, V.; Tini, P.; Carbone, S.F.; Grassi, A.; Biondi, M.; Sebaste, L.; Carfagno, T.; Vanzi, E.; De Otto, G.; Battaglia, G.; et al. Bone texture analysis using CT-simulation scans to individuate risk parameters for radiation-

- induced insufficiency fractures. *Osteoporosis International* 2017, 28, doi:10.1007/s00198-017-3968-5.
9. Tini, P.; Nardone, V.; Pastina, P.; Battaglia, G.; Vinciguerra, C.; Carfagno, T.; Rubino, G.; Carbone, S.F.; Sebaste, L.; Cerase, A.; et al. Perilesional edema in brain metastasis from non-small cell lung cancer (NSCLC) as predictor of response to radiosurgery (SRS). *Neurological Sciences* 2017, 38, doi:10.1007/s10072-017-2876-y.
 10. Tini, P.; Nardone, V.; Pirtoli, L. Is there a potential role for EGFR expression to lead margin reduction in glioblastoma? *J Neurooncol* 2017, 133, doi:10.1007/s11060-017-2406-z.
 11. Nardone, V.; Vinciguerra, C.; Tini, P.; Rocchi, R.; Pirtoli, L. Persistent hiccup after chemo-radiotherapy in nasopharyngeal cancer: an atypical side effect? *Acta Neurol Belg* 2017, 117, 381-383, doi:10.1007/s13760-016-0659-5.
 12. Nardone, V.; Tini, P.; Nioche, C.; Biondi, M.; Sebaste, L.; Mazzei, M.A.; Buonamici, F.B.; Pirtoli, L. Texture analysis of parotid gland as a predictive factor of radiation induced xerostomia: A subset analysis. *Radiotherapy and Oncology* 2017, 122, 321-321, doi:10.1016/j.radonc.2016.09.004.
 13. Tini, P.; Nardone, V.; Pastina, P.; Battaglia, G.; Miracco, C.; Sebaste, L.; Rubino, G.; Cerase, A.; Pirtoli, L. Patients Affected by Unmethylated O(6)-Methylguanine-DNA Methyltransferase Glioblastoma Undergoing Radiochemotherapy May Benefit from Moderately Dose-Escalated Radiotherapy. *Biomed Res Int* 2017, 2017, 9461402, doi:10.1155/2017/9461402.
 14. Tini, P.; Nardone, V.; Pastina, P.; Pirtoli, L.; Correale, P.; Giordano, A. The effects of radiotherapy on the survival of patients with unresectable non-small cell lung cancer. *Expert Rev Anticancer Ther* 2018, 18, 593-602, doi:10.1080/14737140.2018.1458615.
 15. Nardone, V.; Pastina, P.; Giannicola, R.; Agostino, R.; Croci, S.; Tini, P.; Pirtoli, L.; Giordano, A.; Tagliaferri, P.; Correale, P. How to Increase the Efficacy of Immunotherapy in NSCLC and HNSCC: Role of Radiation Therapy, Chemotherapy, and Other Strategies. *Front Immunol* 2018, 9, 2941, doi:10.3389/fimmu.2018.02941.
 16. Mazzei, M.A.; Nardone, V.; Di Giacomo, L.; Bagnacci, G.; Gentili, F.; Tini, P.; Marrelli, D.; Volterrani, L. The role of delta radiomics in gastric cancer. *Quant Imaging Med Surg* 2018, 8, 719-721, doi:10.21037/qims.2018.07.08.
 17. Nardone, V.; Tini, P.; Nioche, C.; Mazzei, M.A.; Carfagno, T.; Battaglia, G.; Pastina, P.; Grassi, R.; Sebaste, L.; Pirtoli, L. Texture analysis as a predictor of radiation-induced xerostomia in head and neck patients undergoing IMRT. *Radiol Med* 2018, 123, 415-423, doi:10.1007/s11547-017-0850-7.
 18. Roviello, G.; Petrioli, R.; Nardone, V.; Rosellini, P.; Multari, A.G.; Conca, R.; Aieta, M. Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study. *Medicine (Baltimore)* 2018, 97, doi:10.1097/MD.00000000000010745.
 19. Nardone, V.; Tini, P.; Croci, S.; Carbone, S.F.; Sebaste, L.; Carfagno, T.; Battaglia, G.; Pastina, P.; Rubino, G.; Mazzei, M.A.; et al. 3D bone texture analysis as a potential predictor of radiation-induced insufficiency fractures. *Quant Imaging Med Surg* 2018, 8, doi:10.21037/qims.2018.02.01.
 20. Tini, P.; Nardone, V.; Pastina, P.; Battaglia, G.; Miracco, C.; Carbone, S.F.; Sebaste, L.; Rubino, G.; Cerase, A.; Pirtoli, L. Epidermal Growth Factor Receptor Expression Predicts Time and Patterns of Recurrence in Patients with Glioblastoma After Radiotherapy and Temozolomide. *World Neurosurgery* 2018, 109, doi:10.1016/j.wneu.2017.10.052.
 21. Biondi, M.; Vanzi, E.; De Otto, G.; Carbone, S.F.; Nardone, V.; Banci

- Buonamici, F. Effects of CT FOV displacement and acquisition parameters variation on texture analysis features. *Phys Med Biol* 2018, 63, 235021, doi:10.1088/1361-6560/aaefac.
22. Nardone, V.; Tini, P.; Marciello, L.; Battaglia, G.; Pastina, P.; Crociani, M.; Cancemi, C.; Vannini, M.; Sebaste, L.; Pirtoli, L. Role of the Appropriateness of the Pelvic Lymphadenectomy and Adjuvant Radiation Therapy in Early-Stage Poorly Differentiated Endometrial Carcinoma. *Indian Journal of Gynecologic Oncology* 2018, 16, doi:ARTN 69 10.1007/s40944-018-0240-7.
23. Nardone, V.; Vinciguerra, C.; Federico, A.; Cerase, A.; Pirtoli, L.; Tini, P. Perilesional edema in brain cancer: Independent prognosticator or epiphenomenon of biomolecular signature? *Radiother Oncol* 2018, 129, 183-184, doi:10.1016/j.radonc.2017.12.020.
24. Correale, P.; Botta, C.; Staropoli, N.; Nardone, V.; Pastina, P.; Ulivieri, C.; Gandolfo, C.; Baldari, T.C.; Lazzi, S.; Ciliberto, D.; et al. Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine. *Oncotarget* 2018, 9, 20539-20554, doi:10.18632/oncotarget.24993.
25. Nardone, V.; Nanni, S.; Pastina, P.; Vinciguerra, C.; Cerase, A.; Correale, P.; Guida, C.; Giordano, A.; Tini, P.; Reginelli, A.; et al. Role of perilesional edema and tumor volume in the prognosis of non-small cell lung cancer (NSCLC) undergoing radiosurgery (SRS) for brain metastases. *Strahlenther Onkol* 2019, doi:10.1007/s00066-019-01475-0.
26. Nardone, V.; Reginelli, A.; Scala, F. Magnetic-Resonance-Imaging Texture Analysis Predicts Early Progression in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiation. *Gastroenterol Res Pract* 2019, 2019, 8505798, doi:10.1155/2019/8505798.
27. Nardone, V.; Reginelli, A.; Scala, F.; Carbone, S.F.; Mazzei, M.A.; Sebaste, L.; Carfagno, T.; Battaglia, G.; Pastina, P.; Correale, P.; et al. Magnetic-Resonance-Imaging Texture Analysis Predicts Early Progression in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiation. *Gastroenterology Research and Practice* 2019, 2019, 8505798-8505798, doi:10.1155/2019/8505798.
28. Reginelli, A.; D'Andrea, A.; Clemente, A.; Izzo, A.; Urraro, F.; Scala, F.; Nardone, V.; Guida, C.; Scialpi, M.; Cappabianca, S. Does multiparametric US improve diagnostic accuracy in the characterization of small testicular masses? *Gland Surg* 2019, 8, doi:10.21037/gs.2019.04.03.
29. Reginelli, A.; Clemente, A.; Renzulli, M.; Maggioletti, N.; Santagata, M.; Colella, G.; Nardone, V.; Golfieri, R.; Brunese, L.; Cappabianca, S. Delayed enhancement in differential diagnosis of salivary gland neoplasm. *Gland Surg* 2019, 8, doi:10.21037/gs.2019.03.03.
30. Nardone, V.; Correale, P.; Guida, C. The Optimal Choice of Local Therapy for Stage IIIA-N2 NSCLC: Is Radiotherapy Inferior to Surgery? *Annals of Thoracic Surgery* 2019, 108, doi:10.1016/j.athoracsur.2019.01.071.
31. Giannicola, R.; D'arrigo, G.; Botta, C.; Agostino, R.; Del Medico, P.; Falzea, A.C.; Barbieri, V.; Staropoli, N.; Del Giudice, T.; Pastina, P.; et al. Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab. *Mol Clin Oncol* 2019, 11, doi:10.3892/mco.2019.1859.
32. Tini, P.; Nardone, V.; Pastina, P.; Marampon, F.; Sebaste, L.; Cerase, A.; Tombolini, V.; Pirtoli, L.; Mazzei, M.A. Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival?

- Clinical Neurology and Neurosurgery 2019, 184, doi:10.1016/j.clineuro.2019.105445.
33. Marampon, F.; Codenotti, S.; Megiorni, F.; Del Fattore, A.; Camero, S.; Gravina, G.L.; Festuccia, C.; Musio, D.; De Felice, F.; Nardone, V.; et al. NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance. *Journal of Cancer Research and Clinical Oncology* 2019, 145, doi:10.1007/s00432-019-02851-0.
 34. Caraglia, M.; Correale, P.; Giannicola, R.; Staropoli, N.; Botta, C.; Pastina, P.; Nesci, A.; Caporlingua, N.; Francini, E.; Ridolfi, L.; et al. GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up. *Front Oncol* 2019, 9, 1102, doi:10.3389/fonc.2019.01102.
 35. Giannicola, R.; D'Arrigo, G.; Botta, C.; Agostino, R.; Del Medico, P.; Falzea, A.C.; Barbieri, V.; Staropoli, N.; Del Giudice, T.; Pastina, P.; et al. Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab. *Mol Clin Oncol* 2019, 11, 81-90, doi:10.3892/mco.2019.1859.
 36. Correale, P.; Saladino, R.E.; Nardone, V.; Giannicola, R.; Agostino, R.; Pirtoli, L.; Caraglia, M.; Botta, C.; Tagliaferri, P. Could PD-1/PDL1 immune checkpoints be linked to HLA signature? *Immunotherapy* 2019, 11, 1523-1526.
 37. Ambrosio, M.R.; Vernillo, R.; De Carolis, S.; Carducci, A.; Mundo, L.; Ginori, A.; Rocca, B.J.; Nardone, V.; Lucenti Fei, A.; Carfagno, T.; et al. Putative Role of Circulating Human Papillomavirus DNA in the Development of Primary Squamous Cell Carcinoma of the Middle Rectum: A Case Report. *Front Oncol* 2019, 9, 93, doi:10.3389/fonc.2019.00093.
 38. Nardone, V.; Vinciguerra, C.; Correale, P.; Guida, C.; Tini, P.; Reginelli, A.; Cappabianca, S. Music therapy and radiation oncology: State of art and future directions. *Complement Ther Clin Pract* 2020, 39, 101124, doi:10.1016/j.ctcp.2020.101124.
 39. Nardone, V.; Tini, P.; Pastina, P.; Botta, C.; Reginelli, A.; Carbone, S.F.; Giannicola, R.; Calabrese, G.; Tebala, C.; Guida, C.; et al. Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab. *Oncol Lett* 2020, 19, 1559-1566, doi:10.3892/ol.2019.11220.
 40. Reginelli, A.; Belfiore, M.P.; Monti, R.; Cozzolino, I.; Costa, M.; Vicidomini, G.; Grassi, R.; Morgillo, F.; Urraro, F.; Nardone, V.; et al. The texture analysis as a predictive method in the assessment of the cytological specimen of CT-guided FNAC of the lung cancer. *Med Oncol* 2020, 37, 54, doi:10.1007/s12032-020-01375-9.
 41. Nardone, V.; Reginelli, A.; Guida, C.; Belfiore, M.P.; Biondi, M.; Mormile, M.; Banci Buonamici, F.; Di Giorgio, E.; Spadafora, M.; Tini, P.; et al. Delta-radiomics increases multicentre reproducibility: a phantom study. *Med Oncol* 2020, 37, 38, doi:10.1007/s12032-020-01359-9.
 42. Vinciguerra, C.; Giorgio, A.; Zhang, J.; Nardone, V.; Brocci, R.T.; Pastò, L.; Niccolai, C.; Stromillo, M.L.; Mortilla, M.; Amato, M.P.; et al. Peak width of skeletonized mean diffusivity (PSMD) and cognitive functions in relapsing-remitting multiple sclerosis. *Brain Imaging and Behavior* 2020, doi:10.1007/s11682-020-00394-4.
 43. Nardone, V.; Falivene, S.; Giugliano, F.M.; Gaetano, M.; Giordano, P.; Muto, M.; Daniele, B.; Guida, C. The role of radiation therapy and systemic therapies in elderly with breast cancer. *Translational Cancer Research* 2020, 9, doi:10.21037/tcr.2019.07.04.
 44. Nardone, V.; Calvanese, M.G.; Mormile, M.; Giugliano, F.M.;

- Correale, P.; Reginelli, A.; Cappabianca, S.; Guida, C. Feasibility of ultra-central stereotactic ablative irradiation in lung cancer undergoing nivolumab: A case report. *Precision Cancer Medicine* 2020, 3.
45. Reginelli, A.; Vacca, G.; Belfiore, M.; Sangiovanni, A.; Nardone, V.; Vanzulli, A.; Grassi, R.; Cappabianca, S. Pitfalls and differential diagnosis on adrenal lesions: current concepts in CT/MR imaging: a narrative review. *Gland Surg* 2020, 9, 2331-2342, doi:10.21037/gs-20-559.
46. Correale, P.; Giannicola, R.; Saladino, R.E.; Nardone, V.; Pirtoli, L.; Tassone, P.; Luce, A.; Cappabianca, S.; Scrima, M.; Tagliaferri, P.; et al. On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer. *Transl Lung Cancer Res* 2020, 9, 1712-1719, doi:10.21037/tlcr-20-536.
47. Nardone, V.; Giugliano, F.M.; Reginelli, A.; Sangiovanni, A.; Mormile, M.; Iadanza, L.; Cappabianca, S.; Guida, C. 4D CT analysis of organs at risk (OARs) in stereotactic radiotherapy. *Radiotherapy and Oncology* 2020, 151, 10-14, doi:10.1016/j.radonc.2020.06.048.
48. Correale, P.; Saladino, R.E.; Giannarelli, D.; Sergi, A.; Mazzei, M.A.; Bianco, G.; Giannicola, R.; Iuliano, E.; Forte, I.M.; Calandruccio, N.D.; et al. HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis. *Cells* 2020, 9, doi:10.3390/cells9091964.
49. Correale, P.; Saladino, R.E.; Giannarelli, D.; Giannicola, R.; Agostino, R.; Staropoli, N.; Strangio, A.; Del Giudice, T.; Nardone, V.; Altomonte, M.; et al. Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosity predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade. *J Immunother Cancer* 2020, 8, doi:10.1136/jitc-2020-000733.
50. Belfiore, M.P.; Reginelli, A.; Maggialelli, N.; Carbone, M.; Giovine, S.; Laporta, A.; Urraro, F.; Nardone, V.; Grassi, R.; Cappabianca, S.; et al. Preliminary results in unresectable cholangiocarcinoma treated by CT percutaneous irreversible electroporation: feasibility, safety and efficacy. *Med Oncol* 2020, 37, 45, doi:10.1007/s12032-020-01360-2.
51. Nardone, V.; Calvanese, M.G.; D'Onofrio, I.; Di Stasio, M.; Vitale, C.; Silvestri, A.; Daniele, B.; Correale, P.; Fierro, P.; Tortoriello, G.; et al. Neck emphysema in a HNSCC cancer patient undergoing concurrent radiotherapy and cetuximab. *Rep Pract Oncol Radiother* 2020, 25, 396-398, doi:10.1016/j.rpor.2020.03.025.
52. Mazzei, M.A.; Giacomo, L.D.; Bagnacci, G.; Nardone, V.; Gentili, F.; Lucii, G.; Tini, P.; Marrelli, D.; Morgagni, P.; Mura, G.; et al. Delta-radiomics and response to neoadjuvant treatment in locally advanced gastric cancer—a multicenter study of GIRCG (Italian Research Group for Gastric Cancer). *Quant Imaging Med Surg* 2021.
53. Reginelli, A.; Clemente, A.; Sangiovanni, A.; Nardone, V.; Selvaggi, F.; Sciaudone, G.; Ciardiello, F.; Martinelli, E.; Grassi, R.; Cappabianca, S. Endorectal Ultrasound and Magnetic Resonance Imaging for Rectal Cancer Staging: A Modern Multimodality Approach. *Journal of clinical medicine* 2021, 10, doi:10.3390/jcm10040641.
54. Nardone, V.; Giannicola, R.; Bianco, G.; Giannarelli, D.; Tini, P.; Pastina, P.; Falzea, A.C.; Macheda, S.; Caraglia, M.; Luce, A.; et al. Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade. *Front Oncol* 2021, 11, 684110, doi:10.3389/fonc.2021.684110.
55. Reginelli, A.; Nardone, V.; Giacobbe, G.; Belfiore, M.P.; Grassi, R.; Schettino, F.; Del Canto, M.; Grassi, R.; Cappabianca, S. Radiomics as a New Frontier of Imaging for Cancer Prognosis: A Narrative Review. *Diagnostics*

2021, 11, 1796.

56. Nardone, V.; Boldrini, L.; Grassi, R.; Franceschini, D.; Morelli, I.; Becherini, C.; Loi, M.; Greto, D.; Desideri, I. Radiomics in the Setting of Neoadjuvant Radiotherapy: A New Approach for Tailored Treatment. *Cancers* (Basel) 2021, 13, doi:10.3390/cancers13143590.
57. Nardone, V.; Giannicola, R.; Giannarelli, D.; Saladino, R.E.; Azzarello, D.; Romeo, C.; Bianco, G.; Rizzo, M.R.; Di Meo, I.; Nesci, A.; et al. Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis. *Life* (Basel) 2021, 11, doi:10.3390/life11111235.
58. Nardone, V.; Reginelli, A.; Grassi, R.; Boldrini, L.; Vacca, G.; D'Ippolito, E.; Annunziata, S.; Farchione, A.; Belfiore, M.P.; Desideri, I.; et al. Delta radiomics: a systematic review. *Radiol Med* 2021, 126, 1571-1583, doi:10.1007/s11547-021-01436-7.
59. Urraro, F.; Nardone, V.; Reginelli, A.; Varelli, C.; Angrisani, A.; Patanè, V.; D'Ambrosio, L.; Roccatagliata, P.; Russo, G.M.; Gallo, L.; et al. MRI Radiomics in Prostate Cancer: A Reliability Study. *Front Oncol* 2021, 11, 805137, doi:10.3389/fonc.2021.805137.
60. Nardone, V.; Reginelli, A.; Vinciguerra, C.; Correale, P.; Calvanese, M.G.; Falivene, S.; Sangiovanni, A.; Grassi, R.; Di Biase, A.; Polifrone, M.A.; et al. Mood Disorder in Cancer Patients Undergoing Radiotherapy During the COVID-19 Outbreak. *Front Psychol* 2021, 12, 568839, doi:10.3389/fpsyg.2021.568839.
61. Porta, C.; Nardone, V.; Gray, S.G.; Correale, P.; Mutti, L. RAMES study: is there really a role for VEGF inhibition in mesothelioma? *The Lancet Oncology* 2021, 22, e532.
62. Bruni, A.; Scotti, V.; Borghetti, P.; Vagge, S.; Cozzi, S.; D'Angelo, E.; Giaj Levra, N.; Fozza, A.; Taraborrelli, M.; Piperno, G.; et al. Corrigendum: A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer (*Front. Oncol.*, (2021), 11, (744956), 10.3389/fonc.2021.744956). *Front Oncol* 2021, 11.
63. Borghetti, P.; Toraci, C.; Imbrescia, J.; Volpi, G.; Lucchini, S.; Guerini, A.E.; Magli, A.; Spiazzi, L.; Reginelli, A.; Cappabianca, S.; et al. The potential role of SPECT/CT in the clinical management of COVID-19 lung cancer patients undergoing radiotherapy. *Ann Nucl Med* 2021, 35, 1174-1176, doi:10.1007/s12149-021-01662-z.
64. De Felice, F.; Boldrini, L.; Greco, C.; Nardone, V.; Salvestrini, V.; Desideri, I. ESTRO vision 2030: the young Italian Association of Radiotherapy and Clinical Oncology (yAIRO) commitment statement. *Radiol Med* 2021, 126, 1374-1376, doi:10.1007/s11547-021-01398-w.
65. Bruni, A.; Scotti, V.; Borghetti, P.; Vagge, S.; Cozzi, S.; D'Angelo, E.; Giaj Levra, N.; Fozza, A.; Taraborrelli, M.; Piperno, G.; et al. A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer. *Front Oncol* 2021, 11.
66. Nardone, V.; Barbarino, M.; Angrisani, A.; Correale, P.; Pastina, P.; Cappabianca, S.; Reginelli, A.; Mutti, L.; Miracco, C.; Giannicola, R.; et al. CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy. *Int J Mol Sci* 2021, 22, doi:10.3390/ijms22168391.
67. Vinciguerra, C.; Giorgio, A.; Zhang, J.; Nardone, V.; Brocci, R.T.; Pasto, L.; Niccolai, C.; Stromillo, M.L.; Mortilla, M.; Amato, M.P.; et al. Peak width of skeletonized mean diffusivity (PSMD) and cognitive functions in

- relapsing-remitting multiple sclerosis. *Brain Imaging Behav* 2021, 15, 2228-2233, doi:10.1007/s11682-020-00394-4.
68. Iorio, G.C.; Salvestrini, V.; Borghetti, P.; De Felice, F.; Greco, C.; Nardone, V.; Fiorentino, A.; Gregucci, F.; Desideri, I. The impact of modern radiotherapy on radiation-induced late sequelae: Focus on early-stage mediastinal classical Hodgkin Lymphoma. A critical review by the Young Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). *Crit Rev Oncol Hematol* 2021, 161, 103326, doi:10.1016/j.critrevonc.2021.103326.
69. Nardone, V.; Reginelli, A.; Vitale, C.; Calvanese, M.G.; Correale, P.; Grassi, R.; Falivene, S.; Sangiovanni, A.; Cappabianca, S.; Guida, C. Feasibility of stereotactic ablative reirradiation in breast cancer patient undergoing palbociclib: a case report. *International Journal of Radiation Research* 2021, 19, 479-482, doi:10.18869/acadpub.ijrr.19.2.471.
70. Nardone, V.; Sangiovanni, A.; Scala, F.; Mormile, M.; D'Onofrio, I.; Giugliano, F.; Vitale, C.; Muto, M.; Reginelli, A.; Cappabianca, S.; et al. Choosing the optimal gated window for defining target volume in lung stereotactic ablative radiotherapy. *International Journal of Radiation Research* 2021, 19, 429-435, doi:10.18869/acadpub.ijrr.19.2.429.
71. Pacifico, P.; Colciago, R.R.; De Felice, F.; Boldrini, L.; Salvestrini, V.; Nardone, V.; Desideri, I.; Greco, C.; Arcangeli, S. A critical review on oligometastatic disease: a radiation oncologist's perspective. *Med Oncol* 2022, 39, 181, doi:10.1007/s12032-022-01788-8.
72. Nardone, V.; Reginelli, A.; Grassi, R.; Vacca, G.; Giacobbe, G.; Angrisani, A.; Clemente, A.; Danti, G.; Correale, P.; Carbone, S.F.; et al. Ability of Delta Radiomics to Predict a Complete Pathological Response in Patients with Loco-Regional Rectal Cancer Addressed to Neoadjuvant Chemo-Radiation and Surgery. *Cancers (Basel)* 2022, 14, doi:10.3390/cancers14123004.
73. Nardone, V.; Reginelli, A.; De Marco, G.; Di Pietro, T.; Grassi, R.; Corte, C.M.D.; Fasano, M.; Ciammella, P.; Vicidomini, G.; Morgillo, F.; et al. The role of coronary artery calcification score in lung cancer patients. *Eur J Radiol* 2022, 147, 110140, doi:10.1016/j.ejrad.2021.110140.
74. Meirson, T.; Nardone, V.; Pentimalli, F.; Markel, G.; Bomze, D.; D'Apolito, M.; Correale, P.; Giordano, A.; Pirtoli, L.; Porta, C.; et al. Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology. *J Transl Med* 2022, 20, 593, doi:10.1186/s12967-022-03744-6.
75. Belfiore, M.P.; Sansone, M.; Monti, R.; Marrone, S.; Fusco, R.; Nardone, V.; Grassi, R.; Reginelli, A. Robustness of Radiomics in Pre-Surgical Computer Tomography of Non-Small-Cell Lung Cancer. *J Pers Med* 2022, 13, doi:10.3390/jpm13010083.
76. Montella, M.; Ciani, G.; Granata, V.; Fusco, R.; Grassi, F.; Ronchi, A.; Cozzolino, I.; Franco, R.; Zito Marino, F.; Urraro, F.; et al. Preliminary Experience of Liquid Biopsy in Lung Cancer Compared to Conventional Assessment: Light and Shadows. *J Pers Med* 2022, 12, doi:10.3390/jpm12111896.
77. Della Corte, C.M.; Ciaramella, V.; Ramkumar, K.; Vicidomini, G.; Fiorelli, A.; Nardone, V.; Cappabianca, S.; Cozzolino, I.; Zito Marino, F.; Di Guida, G.; et al. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC. *J Transl Med* 2022, 20.
78. Francolini, G.; Morelli, I.; Carnevale, M.G.; Grassi, R.; Nardone, V.; Loi, M.; Valzano, M.; Salvestrini, V.; Livi, L.; Desideri, I. Integration between Novel Imaging Technologies and Modern Radiotherapy Techniques: How the Eye Drove the Chisel. *Cancers (Basel)* 2022, 14, doi:ARTN 5277 10.3390/cancers14215277.

79. Nardone, V.; D'Ippolito, E.; Grassi, R.; Sangiovanni, A.; Gagliardi, F.; De Marco, G.; Menditti, V.S.; D'Ambrosio, L.; Cioce, F.; Boldrini, L.; et al. Non-Oncological Radiotherapy: A Review of Modern Approaches. *J Pers Med* 2022, 12, doi:10.3390/jpm12101677.
80. Nardone, V.; Desideri, I.; D'Ambrosio, L.; Morelli, I.; Visani, L.; Di Giorgio, E.; Guida, C.; Clemente, A.; Belfiore, M.P.; Cioce, F.; et al. Nuclear medicine and radiotherapy in the clinical management of glioblastoma patients. *Clinical and Translational Imaging* 2022, 10, 477-493, doi:10.1007/s40336-022-00495-8.
81. Fameli, A.; Nardone, V.; Shekarkar Azgomi, M.; Bianco, G.; Gandolfo, C.; Oliva, B.M.; Monoriti, M.; Saladino, R.E.; Falzea, A.; Romeo, C.; et al. PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach. *Front Oncol* 2022, 12, 911579, doi:10.3389/fonc.2022.911579.
82. Tufano, A.; Cordua, N.; Nardone, V.; Ranavolo, R.; Flammia, R.S.; D'Antonio, F.; Borea, F.; Anceschi, U.; Leonardo, C.; Morrione, A.; et al. Prognostic Significance of Organ-Specific Metastases in Patients with Metastatic Upper Tract Urothelial Carcinoma. *J Clin Med* 2022, 11, doi:10.3390/jcm11185310.
83. Belfiore, M.P.; Russo, G.M.; Gallo, L.; Atripaldi, U.; Tamburrini, S.; Caliendo, V.; Impieri, L.; Del Canto, M.T.; Ciani, G.; Parrella, P.; et al. Secondary Complications in COVID-19 Patients: A Case Series. *Tomography* 2022, 8, 1836-1850, doi:10.3390/tomography8040154.
84. Iori, F.; Bruni, A.; Cozzi, S.; Ciammella, P.; Di Pressa, F.; Boldrini, L.; Greco, C.; Nardone, V.; Salvestrini, V.; Desideri, I.; et al. Can Radiotherapy Empower the Host Immune System to Counterattack Neoplastic Cells? A Systematic Review on Tumor Microenvironment Radiomodulation. *Current Oncology* 2022, 29, 4612-4624.
85. Nardone, V.; Porta, C.; Giannicola, R.; Correale, P.; Mutti, L. Abemaciclib for malignant pleural mesothelioma. *Lancet Oncol* 2022, 23, e237, doi:10.1016/S1470-2045(22)00276-5.
86. Roviello, G.; Nardone, V.; Bonetta, A.; Correale, P.; Molteni, A.; Lazzari, M.C.; Generali, D. Effects of Whole Pelvic Radiotherapy on the Distribution of Lymphocyte Subpopulations in Prostate Cancer Patients. *Am J Clin Oncol* 2022, 45, 105-111, doi:10.1097/COC.0000000000000894.
87. Nardone, V.; Correale, P.; Mutti, L.; Desideri, I.; Romeo, C.; Pastina, P.; Tagliaferri, P.; Caraglia, M.; Reginelli, A.; Pirtoli, L.; et al. Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal End Point? *J Thorac Oncol* 2022, 17, e10-e12, doi:10.1016/j.jtho.2021.09.019.
88. Fasano, M.; D'Onofrio, I.; Belfiore, M.P.; Angrisani, A.; Caliendo, V.; Della Corte, C.M.; Pirozzi, M.; Facchini, S.; Caterino, M.; Guida, C.; et al. Head and Neck Squamous Cell Carcinoma in Elderly Patients: Role of Radiotherapy and Chemotherapy. *Cancers (Basel)* 2022, 14, doi:10.3390/cancers14030472.
89. Salvestrini, V.; Iorio, G.C.; Borghetti, P.; De Felice, F.; Greco, C.; Nardone, V.; Fiorentino, A.; Gregucci, F.; Desideri, I. The impact of modern radiotherapy on long-term cardiac sequelae in breast cancer survivor: a focus on deep inspiration breath-hold (DIBH) technique. *J Cancer Res Clin Oncol* 2022, 148, 409-417, doi:10.1007/s00432-021-03875-1.
90. Russo, G.M.; Mangoni di Santo Stefano, M.L.; Belfiore, M.P.; Annunziata, G.; Zoi, E.; Gallo, L.; Ciani, G.; Urraro, F.; Nardone, V.; Reginelli, A.; et al. Total Severity Score (TSS) comparison in vaccinated and unvaccinated patients during the fourth wave (December 2021 - January 2022) of COVID-19 in Italy. *Eur Rev Med Pharmacol Sci* 2022, 26, 5971-5977,

doi:10.26355/eurev_202208_29538.

91. Vinciguerra, C.; Toriello, A.; Nardone, V.; Romano, D.; Tartaglione, S.; Abate, F.; Landolfi, A.; Barone, P. Temporal muscle thickness and survival in patients with amyotrophic lateral sclerosis. *Neurol Res* 2022, 44, 1006-1010, doi:10.1080/01616412.2022.2096004.
92. Lupattelli, M.; Tini, P.; Nardone, V.; Aristei, C.; Borghesi, S.; Maranzano, E.; Anselmo, P.; Ingrosso, G.; Deantonio, L.; di Monale, E.B.M.B. Stereotactic radiotherapy for brain oligometastases. *Rep Pract Oncol Radiother* 2022, 27, 15-22, doi:10.5603/RPOR.a2021.0133.
93. Correale, P.; Pentimalli, F.; Nardone, V.; Giordano, A.; Mutti, L. CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? *The Lancet Oncology* 2022, 23, e13.
94. Vicidomini, G.; Della Corte, C.M.; Noro, A.; Di Liello, R.; Cappabianca, S.; Fiorelli, A.; Nardone, V.; Messina, G.; Viscardi, G.; Sangiovanni, A.; et al. A Trimodality, Four-Step Treatment including Chemotherapy, Pleurectomy/Decortication and Radiotherapy in Early-Stage Malignant Pleural Mesothelioma: A Single-Institution Retrospective Case Series Study. *Cancers (Basel)* 2022, 14, doi:ARTN 142 10.3390/cancers14010142.
95. Salvestrini, V.; Greco, C.; Guerini, A.E.; Longo, S.; Nardone, V.; Boldrini, L.; Desideri, I.; De Felice, F. The role of feature-based radiomics for predicting response and radiation injury after stereotactic radiation therapy for brain metastases: A critical review by the Young Group of the Italian Association of Radiotherapy and Clinical Oncology (yAIRO). *Transl Oncol* 2022, 15, 101275, doi:10.1016/j.tranon.2021.101275.
96. Nardone, V.; Romeo, C.; D'Ippolito, E.; Pastina, P.; D'Apolito, M.; Pirtoli, L.; Caraglia, M.; Mutti, L.; Bianco, G.; Falzea, A.C.; et al. The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review. *Radiol Med* 2023, doi:10.1007/s11547-023-01602-z.
97. Nardone, V.; Reginelli, A.; De Marco, G.; Natale, G.; Patanè, V.; De Chiara, M.; Buono, M.; Russo, G.M.; Monti, R.; Balestrucci, G.; et al. Role of Cardiac Biomarkers in Non-Small Cell Lung Cancer Patients. *Diagnostics (Basel)* 2023, 13, doi:10.3390/diagnostics13030400.
98. Belfiore, M.P.; Sansone, M.; Monti, R.; Marrone, S.; Fusco, R.; Nardone, V.; Grassi, R.; Reginelli, A. Robustness of Radiomics in Pre-Surgical Computer Tomography of Non-Small-Cell Lung Cancer. *J Pers Med* 2023, 13, doi:ARTN 83 10.3390/jpm13010083.
99. Nardone, V.; Boldrini, L.; Salvestrini, V.; Greco, C.; Petrianni, G.M.; Desideri, I.; De Felice, F. Are you planning to be a radiation oncologist? A survey by the young group of the Italian Association of Radiotherapy and Clinical Oncology (yAIRO). *Radiologia Medica* 2023, 128, 252-260.
100. Grassi F, Granata V, Fusco R, De Muzio F, Cutolo C, Gabelloni M, Borgheresi A, Danti G, Picone C, Giovagnoni A, Miele V, Gandolfo N, Barile A, Nardone V, Grassi R. Radiation Recall Pneumonitis: The Open Challenge in Differential Diagnosis of Pneumonia Induced by Oncological Treatments. *J Clin Med*. 2023 Feb 10;12(4):1442. doi: 10.3390/jcm12041442. PMID: 36835977; PMCID: PMC9964719.
101. Russo GM, Russo A, Urraro F, Cioce F, Gallo L, Belfiore MP, Sangiovanni A, Napolitano S, Troiani T, Verolino P, Sica A, Brancaccio G, Briatico G, Nardone V, Reginelli A. Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment. *Diagnostics (Basel)*. 2023 Feb 20;13(4):793. doi: 10.3390/diagnostics13040793. PMID: 36832281; PMCID: PMC9955870.
102. Nardone V, Romeo C, D'Ippolito E, Pastina P, D'Apolito M, Pirtoli L,

- Caraglia M, Mutti L, Bianco G, Falzea AC, Giannicola R, Giordano A, Tagliaferri P, Vinciguerra C, Desideri I, Loi M, Reginelli A, Cappabianca S, Tassone P, Correale P. The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review. *Radiol Med*. 2023 Mar;128(3):316-329. doi: 10.1007/s11547-023-01602-z. Epub 2023 Feb 14. PMID: 36786970; PMCID: PMC10020247.
103. Nardone V, Gagliardi F, Brancaccio G, Napolitano S, Briatico G, Reginelli A. "RT STRIKES BACK": Radiotherapy in Ultra Elderly with Cutaneous Basal Cell Carcinoma. *Dermatol Pract Concept*. 2023 Apr 1;13(2):e2023110. doi: 10.5826/dpc.1302a110. Epub ahead of print. PMID: 37196260; PMCID: PMC10188184.
104. Marano L, Marmorino F, Desideri I, Carbone L, Rizzo A, Salvestrini V, Roviello F, Cinieri S, Donato V, De Luca R; NutriOnc Research Group. Clinical nutrition in surgical oncology: Young AIOM-AIRO-SICO multidisciplinary national survey on behalf of NutriOnc research group. *Front Nutr*. 2023 Apr 14;10:1045022. doi: 10.3389/fnut.2023.1045022. PMID: 37125048; PMCID: PMC10140427.
105. Nardone V, Belfiore MP, De Chiara M, De Marco G, Patanè V, Balestrucci G, Buono M, Salvarezza M, Di Guida G, D'Angiolella D, Grassi R, D'Onofrio I, Cimmino G, Della Corte CM, Gambardella A, Morgillo F, Ciardiello F, Reginelli A, Cappabianca S. CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial. *Diagnostics (Basel)*. 2023 May 12;13(10):1717. doi: 10.3390/diagnostics13101717. PMID: 37238201; PMCID: PMC10217672.
106. D'Onofrio I, Nardone V, Reginelli A, Cappabianca S. Chemoradiotherapy for Head and Neck Cancer. *Cancers (Basel)*. 2023 May 18;15(10):2820. doi: 10.3390/cancers15102820. PMID: 37345157; PMCID: PMC10216499.
107. Nardone V, Meirson T, De Felice F, Meattini I. Genomic Profiling: Can We Rely on Retrospective Analysis to Drive Changes in Clinical Practice? *J Clin Oncol*. 2023 Jun 6;JCO2300334. doi: 10.1200/JCO.23.00334. Epub ahead of print. PMID: 37279433.
108. Franco D, Granata V, Fusco R, Grassi R, Nardone V, Lombardi L, Cappabianca S, Conforti R, Briganti F, Grassi R, Caranci F. Artificial intelligence and radiation effects on brain tissue in glioblastoma patient: preliminary data using a quantitative tool. *Radiol Med*. 2023 Jul;128(7):813-827. doi: 10.1007/s11547-023-01655-0. Epub 2023 Jun 8. PMID: 37289266.
109. Reginelli A, Patanè V, Urraro F, Russo A, De Chiara M, Clemente A, Atripaldi U, Balestrucci G, Buono M, D'ippolito E, Grassi R, D'onofrio I, Napolitano S, Troiani T, De Vita F, Ciardiello F, Nardone V, Cappabianca S. Magnetic Resonance Imaging Evaluation of Bone Metastases Treated with Radiotherapy in Palliative Intent: A Multicenter Prospective Study on Clinical and Instrumental Evaluation Assessment Concordance (MARTE Study). *Diagnostics (Basel)*. 2023 Jul 10;13(14):2334. doi: 10.3390/diagnostics13142334. PMID: 37510078; PMCID: PMC10378594.
110. Boldrini L, D'Aviero A, De Felice F, Desideri I, Grassi R, Greco C, Iorio GC, Nardone V, Piras A, Salvestrini V. Artificial intelligence applied to image-guided radiation therapy (IGRT): a systematic review by the Young Group of the Italian Association of Radiotherapy and Clinical Oncology (yAIRO). *Radiol Med*. 2024 Jan;129(1):133-151. doi: 10.1007/s11547-023-01708-4. Epub 2023 Sep 23. PMID: 37740838.
111. Moscarella E, Di Brizzi EV, Alpi P, Arcelli A, Badellino S, Bossi P, Calzavara-Pinton PG, Di Stefani A, Dika E, Eibenschutz L, Fagnoli MC, Bruno F, Gravina GL, Grilli Leonulli B, Longo C, Lospalluti L, Nardone V, Pimpinelli N, Quaglino P, Queirolo P, Rubegni P, Tagliaferri L, Troiani T, Vavassori A, Argenziano G. Indications for adjuvant radiotherapy in high-risk squamous cell

carcinoma with clear margins: a Delphi consensus. *Br J Dermatol*. 2023 Dec 13;ljad495. doi: 10.1093/bjd/ljad495. Epub ahead of print. PMID: 38092023.

112. Longo V, Della Corte CM, Russo A, Spinnato F, Ambrosio F, Ronga R, Marchese A, Del Giudice T, Sergi C, Casaluce F, Gilli M, Montrone M, Gristina V, Sforza V, Reale ML, Di Liello R, Servetto A, Lipari H, Longhitano C, Vizzini L, Manzo A, Cristofano A, Paoletti L, Nardone A, De Summa S, Perrone A, Bisceglia C, Derosa C, Nardone V, Viscardi G, Galetta D, Vitiello F. Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy. *Front Immunol*. 2024 Jan 18;14:1289434. doi: 10.3389/fimmu.2023.1289434. PMID: 38304255; PMCID: PMC10830694.

113. Ciammella P, Cozzi S, Borghetti P, Galaverni M, Nardone V, Ruggieri MP, Sepulcri M, Scotti V, Bruni A, Zanelli F, Piro R, Tagliavini E, Botti A, Iori F, Alì E, Bennati C, Tiseo M. Redetermination of PD-L1 expression after chemio-radiation in locally advanced PDL1 negative NSCLC patients: retrospective multicentric analysis. *Front Oncol*. 2024 Jan 31;14:1325249. doi: 10.3389/fonc.2024.1325249. PMID: 38357196; PMCID: PMC10866304.

114. Nardone V, Esposito A, D'Ippolito E, Argenziano G, Reginelli A, Troiani T. "Response to Sajid et al. "Response to Valerio Nardone et al.'s "Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: Aretrospective analysis." J Am Acad Dermatol. 2024 Nov 8:S0190-9622(24)03103-7. doi: 10.1016/j.jaad.2024.10.058. Epub ahead of print. PMID: 39522723.

115. Urraro F, Piscopo M, Giordano N, Russo GM, Gallo L, Magliocchetti S, Giordano DS, Patanè V, Arcaniolo D, Cozzolino I, Nardone V, Cappabianca S, Reginelli A. Diagnostic Value of Contrast-Enhanced Ultrasound in Differentiating Malignant from Benign Small Renal Masses After CT/MRI. *J Clin Med*. 2024 Oct 29;13(21):6478. doi: 10.3390/jcm13216478. PMID: 39518616; PMCID: PMC11545930.

116. Kaidar-Person O, Ratosa I, Franco P, Masiello V, Marazzi F, Pedretti S, Ciabattini A, Leonardi MC, Tramm T, Coles CE, Meattini I, Arenas M, Offersen BV, Boersma LJ, Valentini V, Dodwell D, Poortmans P, Aristei C; Assisi Think Tank Meeting ATTM investigators. The Assisi think tank focus review on postoperative radiation for lobular breast cancer. *Radiother Oncol*. 2024 Oct 11;201:110573. doi: 10.1016/j.radonc.2024.110573. Epub ahead of print. PMID: 39395669.

117. Belfiore MP, Nardone V, D'Onofrio I, Pirozzi M, Sandomenico F, Farese S, De Chiara M, Balbo C, Cappabianca S, Fasano M. Recurrent Versus Metastatic Head and Neck Cancer: An Evolving Landscape and the Role of Immunotherapy. *Biomedicines*. 2024 Sep 12;12(9):2080. doi: 10.3390/biomedicines12092080. PMID: 39335592; PMCID: PMC11428618.

118. Nardone V, Marmorino F, Germani MM, Cichowska-Cwalińska N, Menditti VS, Gallo P, Studiale V, Taravella A, Landi M, Reginelli A, Cappabianca S, Girnyi S, Cwalinski T, Boccardi V, Goyal A, Skokowski J, Oviedo RJ, Abou-Mrad A, Marano L. The Role of Artificial Intelligence on Tumor Boards: Perspectives from Surgeons, Medical Oncologists and Radiation Oncologists. *Curr Oncol*. 2024 Aug 27;31(9):4984-5007. doi: 10.3390/currenol31090369. PMID: 39329997; PMCID: PMC11431448.

119. Nardone V, Bruni A, Franceschini D, Marini B, Vagge S, Ciammella P, Sepulcri M, Cappelli A, D'Angelo E, De Marco G, Angrisani A, Manetta M, Scricciolo M, Guida C, Aiello D, Borghetti P, Cappabianca S. Adjuvant modern radiotherapy in resected pN2 NSCLC patients: results from a multicentre retrospective analysis on acute and late toxicity on behalf of AIRO thoracic oncology study group: the RAC-TAC study. *Radiol Med*. 2024 Nov;129(11):1700-1709. doi: 10.1007/s11547-024-01885-w. Epub 2024 Aug

31. PMID: 39215945; PMCID PMC11554814.
120. De Falco V, Napolitano S, Franco R, Zito Marino F, Formisano L, Esposito D, Suarato G, Napolitano R, Esposito A, Caraglia F, Giugliano MC, Cioli E, Famiglietti V, Bianco R, Argenziano G, Ronchi A, Ciardiello D, Nardone V, D'Ippolito E, Del Tufo S, Ciardiello F, Troiani T. Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma. *Oncoimmunology*. 2024 Aug 26;13(1):2388315. doi: 10.1080/2162402X.2024.2388315. PMID: 39206096; PMCID: PMC11352706.
121. Rubini D, Gagliardi F, Menditti VS, D'Ambrosio L, Gallo P, D'Onofrio I, Pisani AR, Sardaro A, Rubini G, Cappabianca S, Nardone V, Reginelli A. Genetic profiling in radiotherapy: a comprehensive review. *Front Oncol*. 2024 Jul 26;14:1337815. doi: 10.3389/fonc.2024.1337815. PMID: 39132508; PMCID: PMC11310144.
122. Nardone V, Reginelli A, Rubini D, Gagliardi F, Del Tufo S, Belfiore MP, Boldrini L, Desideri I, Cappabianca S. Delta radiomics: an updated systematic review. *Radiol Med*. 2024 Aug;129(8):1197-1214. doi: 10.1007/s11547-024-01853-4. Epub 2024 Jul 17. PMID: 39017760; PMCID: PMC11322237.
123. Russo A, Patanè V, Gagliardi F, Urraro F, Ronchi A, Vitiello P, Sica A, Argenziano G, Nardone V, Reginelli A. Preliminary Experience in Ultra-High Frequency Ultrasound Assessment of Cutaneous Primary Lymphomas: An Innovative Classification. *Cancers (Basel)*. 2024 Jul 4;16(13):2456. doi: 10.3390/cancers16132456. PMID: 39001518; PMCID: PMC11240684.
124. Del Tufo S, Atripaldi U, Nicastro A, Panarese I, Ciardiello D, Nardone V, Selvaggi F, Grassi R, Cappabianca S, Martinelli E, Reginelli A. Identification of perineural invasion at imaging staging as a novel potential risk factor in rectal cancer: A case report. *Radiol Case Rep*. 2024 Jun 15;19(9):3626-3630. doi: 10.1016/j.radcr.2024.05.031. PMID: 38983297; PMCID: PMC11228643.
125. Iorio GC, Denaro N, Livi L, Desideri I, Nardone V, Ricardi U. Editorial: Advances in radiotherapy for head and neck cancer. *Front Oncol*. 2024 Jun 7;14:1437237. doi: 10.3389/fonc.2024.1437237. PMID: 38912069; PMCID: PMC11190330.
126. Martinelli E, Ciardiello D, Martini G, Napolitano S, Del Tufo S, D'Ambrosio L, De Chiara M, Famiglietti V, Nacca V, Cardone C, Avallone A, Cremolini C, Pietrantonio F, Maiello E, Granata V, Troiani T, Cappabianca S, Ciardiello F, Nardone V, Reginelli A. Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial. *Clin Drug Investig*. 2024 Jul;44(7):541-548. doi: 10.1007/s40261-024-01372-0. Epub 2024 Jun 17. PMID: 38886336.
127. Nardone V, Napolitano S, Gagliardi F, Esposito A, Caraglia F, Briatico G, Scharf C, Ronchi A, D'Onofrio I, D'Ippolito E, Russo A, Belfiore MP, Franco R, Argenziano G, Ciardiello F, Reginelli A, Cappabianca S, Troiani T. Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: A retrospective analysis. *J Am Acad Dermatol*. 2024 Oct;91(4):678-683. doi: 10.1016/j.jaad.2024.06.023. Epub 2024 Jun 15. PMID: 38885840.
128. Borghetti P, Costantino G, Santoro V, Mataj E, Singh N, Vitali P, Greco D, Volpi G, Sepulcri M, Guida C, Tomasi C, Buglione M, Nardone V. Artificial Intelligence-suggested Predictive Model of Survival in Patients Treated With Stereotactic Radiotherapy for Early Lung Cancer. *In Vivo*. 2024 May-Jun;38(3):1359-1366. doi: 10.21873/invivo.13576. PMID: 38688600; PMCID: PMC11059897.
129. Gagliardi F, Russo A, Scharf C, Pinto A, Faenza M, D'Ippolito E,

- Argenziano G, Troiani T, Reginelli A, Nardone V. All for one: Collaboration between dermatologist, radiation oncologist and radiologist in the clinical management of "difficult to treat" non melanoma skin cancer. *Clin Transl Radiat Oncol.* 2024 Mar 30;46:100774. doi: 10.1016/j.ctro.2024.100774. PMID: 38596818; PMCID:PMC11001761.
130. Wen R, Huang X, Long J, Guo Y, Wei Y, Lin P, Xie S, Zhao Z, Zhang L, Fan AY, Barbalho SM, Nardone V, Alzeer J, Chen Y, Yu Z. Advances in traditional Chinese herbal medicine and their pharmacodynamic mechanisms in cancer immunoregulation: a narrative review. *Transl Cancer Res.* 2024 Feb 29;13(2):1166-1187. doi: 10.21037/tcr-23-1983. Epub 2024 Jan 24. PMID: 38482437; PMCID: PMC10928617.
131. Urraro F, Piscopo M, Giordano N, Russo GM, Gallo L, Magliocchetti S, Giordano DS, Patanè V, Arcaniolo D, Cozzolino I, Nardone V, Cappabianca S, Reginelli A. Diagnostic Value of Contrast-Enhanced Ultrasound in Differentiating Malignant from Benign Small Renal Masses After CT/MRI. *J Clin Med.* 2024 Oct 29;13(21):6478. doi: 10.3390/jcm13216478. PMID: 39518616; PMCID: PMC11545930.
132. Nardone V, Esposito A, D'Ippolito E, Argenziano G, Reginelli A, Troiani T. Response to Sajid et al's "Response to Valerio Nardone et al's 'Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: A retrospective analysis'". *J Am Acad Dermatol.* 2025 Mar;92(3):e55-e56. doi: 10.1016/j.jaad.2024.10.058. Epub 2024 Nov 9. PMID: 39522723.
133. Nardone V, Reginelli A, Patanè V, Sangiovanni A, Grassi R, Russo A, Correale P, Giordano DS, Zaccaria C, Belfiore MP, Cappabianca S. Prognostic Value of Sarcopenia in Elderly Patients with Metastatic Non-Small-Cell Lung Cancer Undergoing Radiotherapy. *Curr Oncol.* 2024 Oct 25;31(11):6673-6685. doi: 10.3390/curroncol31110492. PMID: 39590123; PMCID: PMC11592436.
134. De Felice F, Malerba S, Nardone V, Salvestrini V, Calomino N, Testini M, Boccardi V, Desideri I, Gentili C, De Luca R, Marano L. Progress and Challenges in Integrating Nutritional Care into Oncology Practice: Results from a National Survey on Behalf of the NutriOnc Research Group. *Nutrients.* 2025 Jan 5;17(1):188. doi: 10.3390/nu17010188. PMID: 39796623; PMCID: PMC11722632.
135. Meattini I, Coles CE, Tramm T, Borghesi S, Krug D, Montero A, Nardone V, Salvestrini V, Valzano M, Valentini V, Aristei C, Poortmans P; Assisi Think Tank Meeting Investigators. Biomarker-Directed Radiotherapy in Breast Cancer: A Narrative Review. *JAMA Oncol.* 2025 Mar 1;11(3):329-339. doi: 10.1001/jamaoncol.2024.5780. PMID: 39820307.
136. Buono M, Russo G, Nardone V, Della Corte CM, Natale G, Rubini D, Palumbo L, Scimone C, Ciani G, D'Onofrio I, Grassi R, Fiorelli A, Morgillo F, Reginelli A, Troncone G, Cappabianca S. New perspectives on inoperable early-stage lung cancer management: Clinicians, physicists, and biologists unveil strategies and insights. *J Liq Biopsy.* 2024 Mar 28;5:100153. doi: 10.1016/j.jlb.2024.100153. PMID: 40027942; PMCID: PMC11863942.
137. De Rosa C, Morgillo F, Amato L, Iommelli F, De Rosa V, Tirino V, Papaccio F, Tuccillo C, Di Guida G, D'Angiolella DM, Di Liello A, Zappavigna S, Caraglia M, Gambardella A, Nardone V, Ramkumar K, Wang Q, Wang J, De Vita F, Ciardiello D, Martinelli E, Troiani T, Napolitano S, Martini G, Servetto A, Byers LA, Ciardiello F, Della Corte CM. DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer. *iScience.* 2025 Feb 1;28(3):111943. doi: 10.1016/j.isci.2025.111943. PMID: 40034862; PMCID: PMC11875153.

Dichiarazione

Il/la sottoscritto/a, sotto la propria personale responsabilità e consapevole delle sanzioni previste dall'art.76 del DPR n.445 del 28/12/2000, per le ipotesi di falsità in atti e dichiarazioni mendaci, dichiara che quanto sopra riportato corrisponde al vero."

"Dichiara, altresì, di essere informato ai sensi e per gli effetti di cui al D.Lgs n.196/2003 (Codice in materia di protezione dei dati personali del 30/06/2003), che i dati personali raccolti saranno trattati, anche con strumenti informatici, esclusivamente nell'ambito del procedimento ECM per il quale la presente dichiarazione viene resa. Autorizzo il trattamento dei miei dati personali ai sensi del D.Lgs sopra menzionato.

Naples,
24 March 2025

SignatureA handwritten signature in black ink, appearing to read 'Valerio Nardone', written in a cursive style.

Alla cortese attenzione del Coordinamento AIRO

Oggetto: Candidatura al ruolo di Consigliere – Gruppo di Studio “Polmone”

Candidato: Valerio Nardone, nato a Napoli in data 16/06/1985

Cari Colleghi,

con grande entusiasmo desidero sottoporre alla Vostra attenzione la mia candidatura a Consigliere del Gruppo di Studio dei tumori polmonari per il biennio 2026–2027.

Dopo la Specializzazione conseguita presso l'Università di Siena nel 2016, ho intrapreso un percorso professionale dedicato con particolare impegno alla patologia polmonare, inizialmente come borsista presso la UOC di Radioterapia di Siena e successivamente, dal 2018, come dirigente medico di I livello presso l'Ospedale del Mare di Napoli e dal 2021 come Ricercatore presso l'Azienda Ospedaliero Universitaria “Luigi Vanvitelli”. In tale sede ho avuto l'opportunità di consolidare la mia esperienza clinica e tecnologica, con particolare attenzione ai trattamenti stereotassici e ai protocolli combinati radio–immunoterapia.

Attualmente ricopro il ruolo di Professore Universitario presso l'Università degli Studi della Campania “Luigi Vanvitelli”, dove porto avanti attività di ricerca e formazione, con un focus sui tumori toracici e sull'innovazione tecnologica applicata alla radioterapia.

Ho avuto l'onore di partecipare attivamente alla vita della nostra Associazione ricoprendo diversi incarichi:

- **Consigliere del Gruppo di Studio Tumori Toracici (2020–2021);**
- **Consigliere AIRO Giovani (2018–2022);**
- **Consigliere del Gruppo di Studio Tumori Gastrointestinali (2022–2023);**
- **Membro della Commissione Scientifica AIRO (2022–2025).**

Queste esperienze mi hanno permesso di crescere professionalmente, confrontandomi con Colleghi di grande valore e partecipando a progetti condivisi che hanno contribuito in modo significativo allo sviluppo della nostra disciplina.

Per il biennio 2026–2027, il mio programma si ispira al lavoro egregio dei coordinamenti precedenti e intende proseguire e rafforzare le linee già tracciate, con una particolare attenzione a:

1. **Tumori toracici (NSCLC e SCLC):** promuovere studi e iniziative formative dedicate a tutte le principali neoplasie toraciche, con focus sui trattamenti multimodali e sull'integrazione radio–immunoterapica;
2. **Dosimetria cardiaca:** approfondire il tema dell'esposizione cardiaca nei trattamenti toracici, analizzandone le implicazioni cliniche e i potenziali effetti tardivi, con l'obiettivo di condividere buone pratiche di pianificazione;
3. **Imaging quantitativo (radiomica e dosiomatica):** incentivare la ricerca e la diffusione delle applicazioni di intelligenza artificiale e analisi avanzata delle immagini, con particolare riferimento alla predizione della tossicità e dei risultati clinici;

Confido che il mio impegno, unito alla preziosa collaborazione di tutti Voi, possa contribuire a proseguire il percorso di crescita di questo Gruppo, che negli ultimi anni ha rappresentato un punto di riferimento fondamentale per la nostra comunità scientifica.

Napoli, 18/08/2025

Grazie,

